Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: Mr Metals who wrote (1030)	12/22/1998 11:36:00 AM
From: MoneyMade	Read Replies (1) \| Respond to of 15987

LIPO---The Liposome Company Signs Agreement With Amgen to Market ABELCET(R) PRINCETON, N.J., Oct. 13 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that Amgen Australia Pty. Ltd., a division of Amgen (Nasdaq: AMGN), will be marketing its product, ABELCET(R), in Australia. The Liposome Company has received approval from the Therapeutic Goods Administration in Australia to market ABELCET(R) (Amphotericin B Lipid Complex Injection) for the first-line treatment of invasive fungal disease. ABELCET(R) is a proprietary drug developed and manufactured by The Liposome Company to treat severe, systemic fungal infections which occur primarily in patients whose immune systems are compromised, such as cancer patients undergoing chemotherapy, bone marrow transplant recipients, solid organ transplant recipients and AIDS patients. "This agreement with Amgen in Australia has significant potential for both companies," said Donald Yarson, Vice President of Sales, Marketing and Business Development of The Liposome Company. "Amgen's sales force has established itself as a significant player in the oncology field in Australia since 1991. We believe this experience will enable them to market ABELCET(R) successfully." ABELCET(R) is a complex between two lipids and amphotericin B, producing a stable ribbon-like complex which has been shown to retain the efficacy associated with amphotericin B while significantly reducing its toxicities, especially those relating to the kidneys. ABELCET(R) is approved in 20 markets world-wide and is the leading lipid-based amphotericin B product in the United States. The marketing agreement also covers the country of New Zealand in which The Liposome Company expects to obtain marketing approval next year. Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology. The Liposome Company is a biopharmaceutical company developing, manufacturing and marketing therapeutic products to treat cancer and related diseases. In addition to ABELCET(R), preparations are underway to file a New Drug Application in the U.S. for the Company's second drug, EVACET(TM) (formerly TLC D-99), liposomal doxorubicin, to treat metastatic breast cancer. The Company's product pipeline includes TLC ELL-12 and bromotaxol for the treatment of various cancers and programs focused on the development of new cancer therapies and vehicles for the delivery of gene therapy. Except for historical information, this press release contains forward-looking statements that involve risks and uncertainties, including but not limited to statements regarding future growth in sales of ABELCET(R) either in this country or abroad, the possibility of obtaining marketing approval for ABELCET(R) in other countries, and the likelihood that EVACET(TM) or any other product can be successfully developed and commercialized. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including the risk factors identified in the Registration Statement on Form S-3 dated October 29, 1997 and in the Company's subsequent SEC filings. This press release is also available at lipo.com.